TPTX
Turning Point Therapeutics, Inc.
Glaxosmithkline Plc bought $8.0M of Turning Point Therapeutics, Inc.
Director
Bought$7,999,965
$45.00Price
177,777Shares
+9%Stake
What TPTX did for a copier
Prices for TPTX after this filing aren't in yet.
Glaxosmithkline Plc's record
3 other buys with 3 months of prices since 2017: on average +15.9% against the S&P 500, and 2 of 3 beat it.
We're building an app that can copy buys like this into your own brokerage. Join the waitlist
Traded Tue, Sep 10. Filed Thu, Sep 12, 4:18 PM ET, after the close. Not investment advice.